Global Heparin Market Outlook 2030

Heparin is an anticoagulant (blood thinner) that prevents forming blood clots. Commonly known as unfractionated heparin, it is a glycosaminoglycan that occurs naturally, and is particularly useful in the treatment of heart attacks and unstable angina. Heparin is injected into the vein or under the skin. The global heparin market is estimated to grow with a CAGR of 4.1% during the forecast period 2021-2030. Factors such as the increasing incidences of venous thromboembolism worldwide, followed by the rising concern for other diseases, such as atrial fibrillations with embolization, peripheral arterial embolism, dialysis, surgeries, and blood transfusions among others, are expected to drive the growth of the global heparin market during the forecast period. Moreover, factors such as the rising expenditure on healthcare, and the rapid advancements in medical research, are also expected to contribute to the market growth in the years to come. The market is further expected to garner a revenue of close to USD 7940 Million by the end of 2030, up from a revenue of about USD 5300 Million in 2020.

The global heparin market is segmented into various segments, which include segmentation by product, route of administration, application, and by region. Based on product, the market is segmented into unfractionated heparin (UFH), low molecular weight heparin (LMWH), and ultra low molecular weight heparin (ULMWH), out of which, the low molecular weight heparin (LMWH) segment is anticipated to garner the largest revenue of over USD 5150 Million by the end of 2030. Moreover, by the end of 2020, the segment garnered a value of USD 3490 Million approximately.

Geographically, the global heparin market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, the market in North America region is anticipated to hold the highest market share throughout the forecast period and further attain a revenue of around USD 3270 Million by the end of 2030.

Some of the prominent industry leaders in the global heparin market that are included in our report are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and others.